Skincare Clinical Studies in Canada and the United States: A Practical Guide

Skincare brands today face increasing pressure to substantiate product performance and safety with real human-based evidence. As both Canadian and US markets become more evidence oriented, well-designed clinical studies are now essential for substantiating claims, satisfying regulators, and building market credibility.

In this guide you will learn how clinical programs are structured, how endpoints are selected, and how regulatory frameworks in Canada and the United States affect design, execution, and commercial application of skincare research.

What Are Skincare Clinical Studies and Why They Are Important

Skincare clinical research refers to structured investigations involving human participants that measure how cosmetic and personal care products impact skin safety, structure, function, or appearance under defined conditions. These studies convert laboratory and bench data into meaningful in vivo outcomes, using validated protocols with clear endpoints and pre-specified statistics. Depending on product category and intended claims, research can range from basic safety and tolerability assessments to more complex efficacy evaluations conducted according to Good Clinical Practice.

Human data is indispensable when brands want to support performance claims that go beyond basic cosmetic positioning. Objective clinical evidence underpins regulatory compliance, trustworthy marketing, and defensible claims in both Canada and the U.S.

Why Clinical Evidence Matters for Regulatory and Commercial Success

In both jurisdictions, manufacturers are legally responsible for ensuring their products are safe for consumers and that any product claims are truthful and not misleading. Although most cosmetic products do not require formal pre-market clinical trials, human evidence is often necessary to substantiate higher-impact claims such as hydration benefits, barrier repair, anti-aging performance, or antibacterial activity.

Clinical data also help brands manage risk after launch. When safety concerns, consumer complaints, or formulation changes arise, baseline clinical evidence provides a benchmark for evaluating new observations and supporting regulatory decision-making.

Common Product Categories in Skincare Clinical Studies

Before advancing into study design, it is important to understand how product classification influences clinical strategy. Different categories carry distinct safety expectations, efficacy endpoints, and regulatory thresholds, all of which guide how protocols are structured and which methodologies are most appropriate. The next section outlines the primary skincare product groups and the evidence typically required to support credible, defensible claims within each category.

Cosmetic and Personal Care Products

This category includes moisturizers, cleansers, serums, eye creams, and masks. Clinical programmes focus on safety, tolerability, and instrumental efficacy measures such as hydration, transepidermal water loss (TEWL), elasticity, pigmentation, and irritation. While regulators do not mandate specific tests for most cosmetics in either country, objective human data strengthen claim substantiation and legal defensibility.

Sunscreens and Photoprotection Products

Sunscreens are unique because they are regulated as over-the-counter drugs in the U.S. and as either non-prescription drugs or natural health products (NHPs) in Canada, depending on active ingredients used. SPF and broad-spectrum designations require controlled in vivo testing to support label claims. Expanded functions, such as DNA damage protection or post-procedure use, may necessitate formal clinical trials.

Antiperspirants and Deodorants

Human testing here typically quantifies sweat reduction and odour control. In the U.S. antiperspirants fall under OTC drug regulations, while in Canada many aluminium-based products are considered cosmetics unless they make therapeutic or hyperhidrosis-related claims.

Antibacterial Skin Products

Products positioned to reduce microbial load often sit at the cosmetic-drug interface, making clinical substantiation particularly important. Endpoints include immediate microbial log reductions and residual effectiveness, along with safety and tolerance assessments.

Wound Care Products and Dressings

These are not standard cosmetics when labelled for compromised skin or healing support. In both countries, many wound care products are regulated as medical devices. As such, human studies often focus on functional performance alongside safety and patient tolerance.

Skin Health Supplements

Products taken orally to influence skin parameters fall under dietary supplement regulations in the U.S. and NHP regulations in Canada. Unlike topical cosmetic studies, which evaluate effects at the site of application, clinical research for oral supplements must demonstrate systemic activity that produces measurable skin benefits.

These studies often include biomarkers, blood nutrient levels, or metabolic indicators in addition to dermatological endpoints, since the mechanism of action relies on ingestion, absorption, and distribution through the body. Relevant outcomes typically include changes in hydration, elasticity, sebum regulation, pigmentation, and overall skin quality, supported by validated instrumental measurements and controlled study designs that can substantiate structure and function claims.

Selecting Clinical Endpoints for Skincare Trials

Clinical endpoints are validated, measurable outcomes used to determine how a skincare product performs under controlled conditions. They link intended claims to objective data and guide regulatory defensibility. Endpoints are selected based on the product category, mechanism of action, and the level of evidence needed to support marketing and compliance objectives.

Hydration and Barrier Function Endpoints

Hydration and barrier integrity can be assessed through corneometry and transepidermal water loss. These endpoints are best suited for moisturizers, hydrating serums, barrier repair creams, and post procedure recovery products, where improved moisture retention or strengthened barrier function is a key claim. Improvements in these measures can support claims such as “improves hydration,” “strengthens the skin barrier,” “reduces moisture loss,” and “provides lasting moisturization.”

Skin pH and Microbiome Safety Assessments

Skin pH and microbiome related metrics help determine whether a product maintains or disrupts the skin’s natural balance. These endpoints are most relevant for cleansers, toners, exfoliants, sensitive skin formulations, and microbiome supportive products that prioritize gentle, non-disruptive performance. Results can substantiate claims like “pH balanced,” “gentle on the microbiome,” “supports skin’s natural flora,” or “non-disruptive to skin barrier function.”

Antibacterial and Antimicrobial Efficacy Measures

Antibacterial activity and residual substantivity evaluate the ability of a product to reduce microbial load and maintain antimicrobial effectiveness. These endpoints are appropriate for antibacterial washes, acne focused cleansers, hygiene products, and hand and body washes that position themselves around cleanliness or breakout control. Supporting data can justify claims such as “reduces bacteria on skin,” “helps prevent breakouts,” “provides long lasting antibacterial protection,” or “supports a cleaner, healthier skin surface.”

Sweat Reduction and Antiperspirant Performance

Sweat reduction studies measure how effectively a product limits perspiration under controlled conditions. This endpoint is designed specifically for antiperspirants and clinical strength sweat control products, including formulations for underarms, feet, and sports applications. Positive outcomes can support claims including “reduces underarm wetness,” “provides 48 hour sweat protection,” “clinically proven sweat control,” or “controls moisture during physical activity.”

Anti-Aging Efficacy and Skin Firmness Endpoints

Anti-aging outcomes such as changes in elasticity or dermal density are commonly used for retinol products, peptide serums, firming creams, and targeted treatments developed to address age related skin changes. These endpoints help quantify improvements in firmness, bounce, and structural resilience. Improvements in these measures can substantiate claims like “enhances skin firmness,” “improves elasticity,” “supports collagen rich skin,” or “helps reduce visible signs of aging.”

Surface Topography and Wrinkle Depth Analysis

Surface topography and wrinkle depth assessments quantify changes in fine lines and wrinkles, making them ideal for wrinkle creams, retinoid based formulations, exfoliating treatments, and eye contour products. These endpoints rely on high resolution imaging and advanced skin surface analysis tools. Outcomes can support claims such as “reduces the appearance of wrinkles,” “smooths fine lines,” “improves skin texture,” and “visibly refines the skin surface.”

Pigmentation, Brightening, and Tone Evenness

Pigmentation and tone uniformity assessments support claims related to brightening or improving the overall appearance of the complexion. These endpoints are best suited for vitamin C serums, hyperpigmentation treatments, exfoliating acids, and complexion correcting skincare. They can substantiate claims including “brightens skin,” “improves tone uniformity,” “reduces dark spots,” or “visibly enhances radiance.”

Periorbital Testing for Dark Circles and Puffiness

Periorbital analyses measure changes in puffiness, dark circles, and fine lines around the eyes. These endpoints align with caffeine eye serums, peptide eye creams, and targeted eye treatments formulated to improve the appearance of the periorbital region. Results can support claims such as “reduces puffiness,” “diminishes dark circles,” “smooths eye area fine lines,” or “brightens the look of tired eyes.”

Skincare Study Design and Participant Considerations

Choice of study design and participant selection critically determines the strength of claim substantiation. Well-controlled designs help ensure observed effects reflect the product’s performance rather than external variables.

Randomized Controlled Trials

Randomized controlled trials remain the highest standard for minimizing systematic bias and generating statistically rigorous data. By allocating participants to treatment and control groups through randomization, these studies strengthen internal validity and help ensure that observed effects can be attributed to the product rather than confounding variables. This design is particularly well suited for products making advanced or mechanism driven claims, such as anti-aging serums, retinol or peptide based treatments, hyperpigmentation therapies, oral skin health supplements, and any formulation intended to demonstrate measurable, clinically meaningful improvements.

Split-Face and Split-Body Models

Split-face and split-body designs allow each participant to act as their own control, which significantly reduces inter subject variability and increases the sensitivity of the analysis. These models are highly effective for evaluating topical products where localized comparison is possible, including moisturizers, barrier repair creams, exfoliating treatments, brightening serums, eye contour products, and other formulations intended to produce visible or measurable changes on a defined area of skin. They are particularly advantageous when working with smaller sample sizes or when detecting subtle differences between test and control conditions.

Parallel Group Studies and Vehicle Controls

Parallel group studies are appropriate when split-face or split body designs are not feasible, such as when full face or full body application is required or when treatment effects may influence surrounding skin. In these designs, different participant groups receive distinct interventions, allowing for direct comparison between the test product, placebo, or vehicle. Vehicle controlled studies are particularly important for formulations where the active ingredient is expected to drive the primary effect, since they help isolate the active’s contribution from that of the base formulation. This approach is especially useful for retinoids, peptide serums, anti-aging creams, prescription adjacent cosmetic products, brightening agents, and targeted treatments where differentiating the active’s performance is essential for claim substantiation.

Importance of Defined Inclusion and Exclusion Criteria

Clear inclusion and exclusion criteria ensure that the enrolled population reflects the intended user group and that external factors do not confound study outcomes. Defining parameters such as Fitzpatrick type, skin condition severity, age range, comorbidities, and use of interfering products helps protect internal validity and supports the credibility of the resulting claims. Rigorous participant selection is particularly critical for studies involving acne treatments, anti-aging products, hyperpigmentation therapies, and products designed for sensitive or compromised skin, where variability can significantly influence observed results and attract regulatory scrutiny.

Safety and Sensitivity in Clinical Protocols for Skincare Trials

Clinical study protocols must address both immediate and cumulative exposures. Products intended for daily or extended use, use on compromised skin, or in sensitive populations often require a higher threshold of safety evidence to satisfy regulators and meet consumer expectations.

Immediate Tolerability and Acute Dermal Response Evaluation

Clinical protocols must begin by characterizing acute dermal responses following initial product application. Early phase assessments typically include dermatologist conducted visual grading, participant reported tolerability scores, and instrumental measurements such as colorimetry or TEWL if transient barrier disruption is expected. These evaluations help identify erythema, stinging, burning, or pruritus that may present within minutes to hours of application. Establishing acute tolerability is essential for confirming that the investigational product is appropriate for repeated exposure and for determining whether any protocol modifications or precautionary measures are required prior to initiating longer term use.

Cumulative Irritation, Sensitisation, and Longitudinal Safety Monitoring

Because adverse effects such as cumulative irritation, delayed onset sensitivity, or progressive barrier impairment may only emerge under repeated or prolonged exposure, protocols must incorporate structured longitudinal assessments. Cumulative irritation studies quantify irritation burden across sequential applications, often using weighted scoring systems that capture both intensity and duration of reactions.

Repeat insult patch testing can be employed to evaluate sensitization potential through controlled induction and challenge phases. Multi timepoint evaluations allow investigators to observe trajectory patterns, detect subclinical responses, and characterize the product’s safety profile under conditions that approximate real world use. This data enables differentiation between true product related effects and transient adaptive responses.

Advanced Safety Requirements for High Risk and Special Use Populations

Products formulated for daily or long term use, application on compromised or post procedure skin, or use in populations with heightened reactivity require an expanded safety framework. Protocols for these categories often incorporate extended observation windows, dermatopathologist review where warranted, and targeted biomarker assessments to evaluate inflammation, barrier integrity, or subclinical irritation. Inclusion of predefined stopping rules, independent safety oversight, and rigorous adverse event documentation strengthens participant protection and supports regulatory confidence in the data. For formulations positioned as suitable for sensitive, atopic, paediatric, or post procedure skin, these elevated methodological expectations help ensure that the safety evidence aligns with both regulatory requirements and increasingly sophisticated consumer expectations.

Final Remarks

Skincare clinical programmes go beyond basic safety checks. They are strategic tools that enhance regulatory compliance, elevate marketing credibility, support premium positioning, and foster trust with professionals and consumers alike. By understanding the regulatory environments in Canada and the United States and aligning study design with intended claims, brands can maximise the impact and defensibility of their clinical evidence.

Partner with SNI Clinical Research for Evidence Based Cosmetic Product Claims

SNI Clinical Research supports cosmetic and personal care brands in generating human data needed to substantiate claims, meet regulatory expectations, and stand out in competitive markets. Our team designs and conducts high quality clinical studies tailored to your formulation, target claims, and regulatory category, swith capabilities that include safety assessments, cumulative irritation testing, split-face and parallel group efficacy studies, and advanced instrumental measurements.

With a dedicated clinical facility in Winnipeg and access to diverse participant populations, we deliver reliable, defensible data that supports both compliance and marketing strategy.

Connect with our team to explore how a customized clinical program can strengthen your product’s credibility and accelerate your path to market.

Send us a request for an introductory call using the form below!

FAQ

How are participants recruited for skincare clinical studies?

Participant recruitment is based on predefined inclusion and exclusion criteria that reflect the intended user population. Recruitment strategies consider factors such as age, Fitzpatrick skin type, skin condition severity, and prior product use. Diversity is particularly important for claims related to pigmentation, anti-aging, acne, and sensitive skin, since these outcomes vary across demographic groups. A structured recruitment approach strengthens data relevance and helps ensure that results apply to real world users.

Do environmental or seasonal factors affect study outcomes?

Yes. Skin responses can shift significantly with changes in humidity, temperature, and UV exposure. Clinical protocols therefore stabilize environmental variables by using controlled testing rooms, consistent humidity ranges, and fixed temperature settings. Seasonal timing is also important, especially for hydration, barrier function, and photoprotection studies. Standardizing these factors helps reduce variability and increases confidence in the observed results. Winnipeg’s climate naturally complements this approach because it experiences pronounced seasonal extremes, low humidity winters, and high UV summers, providing access to a wide range of environmental conditions that can influence skin physiology. This makes Winnipeg an ideal location for generating data that is both controlled and broadly representative of real world use scenarios.

How are clinical instruments standardized to ensure accurate measurements?

Instrumentation used in skincare studies, such as corneometers, TEWL devices, and high resolution imaging systems, must undergo routine calibration and performance checks. Operators are trained on standardized procedures to minimize inter-rater variability, and all measurements follow validated protocols. These controls ensure that results reflect true product performance rather than measurement error or operator technique.

What role do biostatistics and data management play in cosmetic clinical trials?

Biostatistics is essential for determining sample size, selecting appropriate statistical tests, and ensuring that the study is powered to detect meaningful differences. Data management processes include data entry validation, query resolution, blinded assessments where appropriate, and secure data handling consistent with established research practices. These steps protect data integrity and support defensible claims.

How is clinical data translated into compliant cosmetic claims?

Clinical findings must be interpreted within regulatory boundaries for cosmetic products in Canada and the United States. Evidence supports structure and function level claims, such as improvements in hydration, firmness, or tone uniformity, but results cannot be translated into therapeutic or disease modifying language. Harmonizing clinical data with acceptable cosmetic claims ensures regulatory compliance while still highlighting product performance in a credible, consumer friendly way.

---

✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.